C2orf82, also known as small novel rich in cartilage (SNORC), is a gene located on chromosome 2 that is known to play a role in chondrocyte maturation.
For a long time, α2-adrenoceptor antagonists have been successfully used as adjunct therapy to improve pharmacotherapy of antipsychotics, antidepressants or anti-parkinsonian drugs.
Alkermes plc’s recent update on sales of the schizophrenia drug Lybalvi (also indicated for bipolar I disorder) along with positive phase III data from Karuna Therapeutics Inc. from tests of Karxt (xanomeline plus trospium) shone more light on the troublesome indication, where Cerevel Therapeutics Holdings Inc. is advancing emraclidine in what could be a registrational phase II study.
Therapeutic Solutions International Inc. has announced promising data on the use of Campbellcell for treatment of bipolar disorder by the company's suicide prevention-based spin-off Campbell Neurosciences Inc.
Noninvasive electrical stimulation of the brain for 20 minutes per session over four days has been demonstrated to improve both working- and long-term memory for at least one month, in people ages 65 to 88.
Two large-scale studies provide new data on genes, inherited variations, and de novo mutations associated with autism spectrum disorder. Some of them are also associated with other neurological conditions, like developmental delay, or schizophrenia.
Following the readout of a phase II trial evaluating its COVID-19 oral antiviral Pentarlandir (SNB-01), Taiwan’s Syneurx International Corp. said it expects to launch a phase III test of the candidate in the next few months.
Shares in Karuna Therapeutics Inc. soared Aug. 8 as the biotech moved closer to a breakthrough for schizophrenia therapy after its potential first-in-class drug Karxt (xanomeline + trospium) met its goals in a closely watched phase III trial. Analysts said results from the Emergent-2 trial were at the top end of what was expected, lifting Karuna’s shares (NASDAQ:KRTX) 71.8% to a 52-week high of $241.19.
Shares in Medincell SA dropped 29.1% Apr. 20 on news that the U.S. FDA slapped a complete response letter (CRL) on an NDA for an extended release, long-acting formulation of risperidone, which it is co-developing with Teva Pharmaceuticals Industries Ltd. as a maintenance treatment for schizophrenia.
With phase III data due from Karuna Therapeutics Inc. with its combo Karxt therapy for schizophrenia, interest is rising in the historically difficult space. Karxt pairs xanomeline, a muscarinic receptor agonist that preferentially stimulates M1 and M4 muscarinic receptors, with trospium, an approved muscarinic receptor antagonist that does not measurably cross the blood-brain barrier, confining its effects to peripheral tissues.
